Stocks · News reference
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumorsZolucatetide directly inhibits β-catenin:TCF, targeting the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Parabilis Medicines, Inc. announced that its management team, including CEO Dr. Mathai Mammen, will participate in three investor conferences throughout November 2026.
Parabilis Medicines presented updated safety and efficacy data for its lead candidate, zolucatetide, at the ESMO Congress 2026, showing strong clinical results in patients with desmoid tumors.
HC Wainwright & Co. has initiated coverage on Parabilis Medicines, Inc. with a "Buy" rating and a price target of $40.00 per share.
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.